Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Anika Therapeutics (ANIK) Research & Development (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Research & Development for 16 consecutive years, with $6.5 million as the latest value for Q4 2025.

  • Quarterly Research & Development fell 0.85% to $6.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $25.8 million through Dec 2025, up 0.88% year-over-year, with the annual reading at $25.8 million for FY2025, 0.88% up from the prior year.
  • Research & Development for Q4 2025 was $6.5 million at Anika Therapeutics, down from $6.9 million in the prior quarter.
  • The five-year high for Research & Development was $8.9 million in Q2 2023, with the low at -$3.3 million in Q4 2023.
  • Average Research & Development over 5 years is $5.9 million, with a median of $6.5 million recorded in 2024.
  • The sharpest move saw Research & Development tumbled 135.2% in 2022, then skyrocketed 294.7% in 2024.
  • Over 5 years, Research & Development stood at $6.0 million in 2021, then crashed by 135.2% to -$2.1 million in 2022, then plummeted by 58.24% to -$3.3 million in 2023, then surged by 294.7% to $6.5 million in 2024, then fell by 0.85% to $6.5 million in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $6.5 million, $6.9 million, and $6.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.